Drugs / Biapenem
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01772836 | Mar 2013 | bacterial infectious disease | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biapenem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01772836 ↗ |
| Route | Intravenous | “Intravenous Biapenem and RPX7009, administered alone and in combination” NCT01772836 ↗ |